Care Access and Eli Lilly and Company Partner to Increase Diversity in Oncology Trials

Care Access, the decentralized research organization (DRO), announced its expanded partnership with Eli Lilly and Company (Lilly) to broaden patient access to clinical trials and increase representation of minority group members, including African American, Hispanic, and LatinX populations.

Lilly has tapped Care Access in its Phase III breast cancer clinical trial, eMonarcHER, designed to evaluate the safety and efficacy of Abemaciclib (LY2835219) in participants with hormone receptor positive and human epidermal receptor II positive, high risk, early breast cancer who are taking hormone therapy after surgery.

This study aims to engage diverse groups of physicians and patients to conduct research that is more fully representative of the U.S. population. To increase enrollment, Care Access will utilize its Patient Access team to establish and foster local community partners including health care systems, physician groups, diversity-focused groups, advocacy groups, and community centers that serve underrepresented minority populations.

More on their partnership